https://neurofixpharma.com/wp-content/uploads/2022/11/neurofix-acto-salamanca02.jpeg
1045
1600
Pablo Montes
https://neurofixpharma.com/wp-content/uploads/2022/05/neurofix-1-2.svg
Pablo Montes2022-11-28 08:46:372023-06-09 09:51:59Neurofix Pharma presenta los exitosos resultados de la fase IIA de su ensayo clínico ante instituciones y empresarios en Salamanca
https://neurofixpharma.com/wp-content/uploads/2022/11/neurofix-acto-salamanca02.jpeg
1045
1600
Pablo Montes
https://neurofixpharma.com/wp-content/uploads/2022/05/neurofix-1-2.svg
Pablo Montes2022-11-28 08:46:372023-07-03 10:32:38Neurofix Pharma presents the successful results of its phase IIA clinical trial to institutions and businessmen in Salamanca
https://neurofixpharma.com/wp-content/uploads/2022/11/manueco-neurofix-scaled.jpg
1706
2560
Pablo Montes
https://neurofixpharma.com/wp-content/uploads/2022/05/neurofix-1-2.svg
Pablo Montes2022-11-11 15:42:282023-06-09 06:55:40Mañueco visita las oficinas de Neurofix Pharma, la primera biotecnológica de Castilla y León en finalizar con éxito la fase IIA de un ensayo clínico
https://neurofixpharma.com/wp-content/uploads/2022/11/manueco-neurofix-scaled.jpg
1706
2560
Pablo Montes
https://neurofixpharma.com/wp-content/uploads/2022/05/neurofix-1-2.svg
Pablo Montes2022-11-11 15:42:282023-07-03 10:33:50Mañueco visits the offices of Neurofix Pharma, the first biotech company in Castilla y León to successfully complete phase IIA of a clinical trial
https://neurofixpharma.com/wp-content/uploads/2022/11/equipo-neurofix.jpg
1333
2000
Pablo Montes
https://neurofixpharma.com/wp-content/uploads/2022/05/neurofix-1-2.svg
Pablo Montes2022-11-10 09:03:452023-06-09 09:52:11Neurofix Pharma entra en el ‘club de los elegidos’ al llegar a la última fase de una de las convocatorias de la UE más competitivas
https://neurofixpharma.com/wp-content/uploads/2022/11/equipo-neurofix.jpg
1333
2000
Pablo Montes
https://neurofixpharma.com/wp-content/uploads/2022/05/neurofix-1-2.svg
Pablo Montes2022-11-10 09:03:452023-07-03 10:34:08Neurofix Pharma enters the ‘club of the chosen ones’ by reaching the last phase of one of the most competitive EU calls.
